The Russian Defence Ministry and the national research center for epidemiology and Microbiology named after N. F. Gamalei are finalizing preparations for the start of clinical trials of a vaccine against coronavirus infection
The Russian Defence Ministry and the National research center for epidemiology and microbiology named after N.F.Gamalei are finalizing preparations for the start of clinical trials of a Russian vaccine against a new coronavirus infection on volunteers.
In the coming days, the first group of volunteers will be vaccinated at the end of the two – week isolation period, the main purpose of which is to check the safety and tolerability of the vaccine components.
The quantitative and qualitative parameters of the sample of volunteers, including the ratio of military and civilian personnel who will be given the new vaccine, have been agreed by the Russian Ministry of Health.
Based on the results of vaccination of the first group, the rest of the volunteers will be successively vaccinated with the components of the vaccine to assess the effectiveness of the vaccine and study the process of developing a humoral immune response (antibodies).
Currently, the health status of all military and civilian volunteers who arrived to participate in the experiment is good, and they continue to be under the continuous control of military medical specialists. Every day, a set of necessary measures is carried out to monitor the main vital indicators of volunteers and study a number of special parameters. Blood tests for IgG and IgM antibodies, oropharyngeal smear for PCR diagnostics on CoViD-19 are taken.
All volunteers have a high degree of motivation, well-tolerated quarantine and preparation for the main phase of testing.
Tests of the Russian vaccine against the new coronavirus infection CoViD-19 are conducted jointly by the Russian Ministry of Defence and the National research center for epidemiology and microbiology named after N.F.Gamalei.
Tests of the vaccine for toxicity, safety, immunogenicity and protective effectiveness on large and small animals were conducted at the 48th Central research institute of the Russian Ministry of Defence.
The selection of military personnel of the Russian Armed Forces to participate in the vaccine trials was carried out exclusively on a voluntary basis. All participants are officers, ensigns, and military personnel serving under contract in various units of the Russian Defence Ministry's NBC protection troops and medical institutions.
On May 26, this year, during a videoconference with Russian President Vladimir Putin, Russian Defence Minister General of the Army Sergei Shoigu reported that the 48th Central Research Institute of the Russian Defence Ministry's NBC protection troops, together with the National research center for epidemiology and microbiology named after N. F. Gamalei of the Ministry of Health, is developing a recombinant vaccine against a new coronavirus infection. Clinical trials are scheduled to be completed by the end of July this year.